Unit of Geriatric Pharmacoepidemiology, Italian National Research Center on Aging (INRCA), C.da Muoio Piccolo, I-87100, Cosenza, Italy.
Drug Saf. 2012 Jan;35 Suppl 1:21-8. doi: 10.1007/BF03319100.
Balanced and safe prescribing is difficult to achieve in frail older adults with multiple comorbid diseases. For this reason, great efforts have been made in the search for interventions to improve efficacy, safety and appropriateness of prescriptions in this vulnerable population. Among these interventions, the avoidance of medications that are considered to be inappropriate, i.e. potentially inappropriate medications (PIMs), has been considered a valuable treatment option. The aim of the present review was to summarize evidence about the use of explicit criteria for PIMs to reduce the risk of adverse drug reactions (ADRs) in older people. A PIM is a drug in which the risk of an adverse event outweighs its clinical benefit, particularly when there is evidence in favour of a safer or more effective alternative therapy for the same condition. Explicit criteria have been developed to identify PIMs, and among these, the Beers criteria have been the most frequently applied until recently. However, evidence suggests that such criteria can not easily be applied in European countries: several drugs listed in the 2003 Beers criteria were rarely prescribed or were not available in Europe and 2003 Beers-listed PIMs were not associated with ADRs in some studies. In the past few years, START/STOPP criteria have been developed and applied in several different studies and populations showing a greater ability to predict ADRs with respect to Beers criteria and to prevent potentially inappropriate prescribing. In 2012, Beers criteria have been updated using an evidence-based approach and future studies will investigate the impact of these and other criteria coming from ongoing studies on clinical outcomes relevant to geriatric populations.
在患有多种合并症的体弱老年人中,实现平衡和安全的处方开具颇具难度。出于这个原因,人们做出了巨大努力,寻找干预措施来提高这一脆弱人群的处方疗效、安全性和适宜性。在这些干预措施中,避免使用被认为不合适的药物(即潜在不适当药物,PIMs)已被视为一种有价值的治疗选择。本综述的目的是总结有关使用明确的 PIM 标准来降低老年人发生不良反应(ADR)风险的证据。PIM 是指一种药物,其发生不良反应的风险超过了其临床获益,特别是当有证据支持针对同一病症使用更安全或更有效的替代疗法时。已经制定了明确的标准来识别 PIMs,其中 Beers 标准是迄今为止最常应用的标准。然而,有证据表明,这些标准在欧洲国家难以轻易应用:2003 年 Beers 标准中列出的几种药物在欧洲很少开处方或不可用,并且在一些研究中,2003 年 Beers 标准列出的 PIMs 与 ADR 无关。在过去几年中,已经制定并在多项不同的研究和人群中应用了 START/STOPP 标准,这些标准在预测 ADR 方面比 Beers 标准具有更大的能力,并能防止潜在的不适当处方。2012 年,Beers 标准采用了循证方法进行了更新,未来的研究将调查这些标准以及正在进行的研究中产生的其他标准对与老年人群相关的临床结果的影响。